Description: Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.
Home Page: www.cardaxpharma.com
2800 Woodlawn Drive
Honolulu,
HI
96822
United States
Phone:
808 457 1400
Officers
| Name | Title |
|---|---|
| Mr. David G. Watumull | Chairman & CEO |
| Mr. David M. Watumull | COO & CFO |
| Mr. Gilbert Shin | VP of Retail Sales & Marketing |
| Dr. Jon L. Ruckle M.D. | Chief Medical Officer |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0.0008 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 10 |